<DOC>
	<DOCNO>NCT02790320</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety eribulin standard clinical practice patient locally recurrent metastatic advance breast cancer .</brief_summary>
	<brief_title>Eribulin Halaven Use For Treatment Advanced Breast Cancer</brief_title>
	<detailed_description>This observational , cross-sectional , retrospective , multicenter study conduct Spain . During year authorization drug European Medicines Agency ( EMA ) , patient compassionate use program ( public site ) patient treated private site ( purchase restriction ) receive least 1 dose treatment eribulin per approve label 17 Spanish site high number treat case period ( minimum 3 patients/site ) enrol observational study . Approximately 112 patient enrol study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Inclusion criterion : 1 . Patients diagnose locally recurrent metastatic advance breast cancer , previously treat taxanes anthracyclines , unless indicate . 2 . Clinical and/or radiological documentation location extension disease time start treatment eribulin . Patients measurable disease patient nonmeasurable lesion eligible . 3 . Medical history documentation include analytical control data ( blood count serum chemistry include hepatic renal function ) carry least one week start treatment eribulin . ( Determining CA153 tumor marker indispensable ) . 4 . Eribulin monotherapy ( least 1 dose ) April 2011 March 2012 , inclusive . 5 . Availability medical history allow monitor clinical progression patient treatment eribulin . Exclusion criterion : 1 . Diagnosis type cancer last 5 year , except nonmelanoma skin cancer , cervical intraepithelial neoplasia contralateral breast cancer . 2 . Patients receive antitumor treatment , whether conventional experimental , week prior start treatment eribulin . Treatment bisphosphonate corticoid allow clinically indicate start 28 day treatment eribulin . 3 . Lack clinical status documentation complete treatment eribulin , least , administer 3 initial cycle . This arise follow case ( exclude ) : 1 . Patients whose Medical History state reason date interruption treatment eribulin subsequent clinical progression . 2 . Patients still undergo treatment eribulin March 31 , 2012 , data least first 3 cycle .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Eribulin mesylate</keyword>
	<keyword>Halaven</keyword>
	<keyword>Breast cancer</keyword>
</DOC>